MINDCURE's first line of mushroom-based nootropics now available for sale.
MINDCURE's first line of mushroom-based nootropics now available for sale.
Dr. Dan Engle, a noted expert in neurology, will lead MINDCURE's psychedelic drug research on traumatic brain injury
Legalized psychedelic drugs are urgently needed to address the Mental Health Crisis. Democrats and Republicans epitomize inertia. The irresistible force meets the immovable object.
Mydecine closes on CAD$17.25 million, with full over-allotment exercised.
MINDCURE adds bioinformatics to its drug development platform.
Psychedelic stock warrants have already produced some phenomenal gains for investors. Now a new series of 5-year warrants is trading.
MindMed inks a new partnership for drug development and expands its pipeline.
Mind Cure has listed the warrants for trading from its recent financing. Warrants are valid until February 10, 2026, at an exercise price of CAD$0.80.
Mind Cure closes on a CAD$23 million bought deal financing, after the full over-allotment was exercised.
Field Trip opens a psychedelic research facility in Jamaica, in partnership with University of the West Indies.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now